Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loratadine vs Diosmin/Hesperidin for Vinca Alkaloid Neuropathy
NCT05243706Phase 3Unknown
- Sponsor
- Ain Shams University
- Start
- Mar 2022
- Primary completion
- Sep 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Covalent Small Molecules
01
Overview
Phase 3, randomised, open-label trial of loratadine, diosmin and hesperidin in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by Ain Shams University. Primary endpoints: Neuropathy Pain Intensity, Pain Quality (Sensory and Pain) and 2 more. Status: unknown.
02
Drugs
loratadinediosminhesperidin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05243706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243706.